BR112013009709A2 - cisteína e absorção de alimento - Google Patents

cisteína e absorção de alimento

Info

Publication number
BR112013009709A2
BR112013009709A2 BR112013009709A BR112013009709A BR112013009709A2 BR 112013009709 A2 BR112013009709 A2 BR 112013009709A2 BR 112013009709 A BR112013009709 A BR 112013009709A BR 112013009709 A BR112013009709 A BR 112013009709A BR 112013009709 A2 BR112013009709 A2 BR 112013009709A2
Authority
BR
Brazil
Prior art keywords
cysteine
food absorption
malnutrition
prevention
treatment
Prior art date
Application number
BR112013009709A
Other languages
English (en)
Portuguese (pt)
Inventor
Denis Breuille
Isabelle Papet
Karine Vidal
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43304791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013009709(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112013009709A2 publication Critical patent/BR112013009709A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
BR112013009709A 2010-10-21 2011-10-19 cisteína e absorção de alimento BR112013009709A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10188399A EP2444083A1 (en) 2010-10-21 2010-10-21 Cysteine and food intake
PCT/EP2011/068231 WO2012052463A1 (en) 2010-10-21 2011-10-19 Cysteine and food intake

Publications (1)

Publication Number Publication Date
BR112013009709A2 true BR112013009709A2 (pt) 2016-07-19

Family

ID=43304791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009709A BR112013009709A2 (pt) 2010-10-21 2011-10-19 cisteína e absorção de alimento

Country Status (15)

Country Link
US (1) US9233090B2 (enExample)
EP (2) EP2444083A1 (enExample)
JP (1) JP6160832B2 (enExample)
CN (1) CN103269697A (enExample)
AU (1) AU2011317627B2 (enExample)
BR (1) BR112013009709A2 (enExample)
CA (1) CA2815109C (enExample)
DK (1) DK2629769T3 (enExample)
ES (1) ES2654344T3 (enExample)
MX (1) MX2013004371A (enExample)
PH (1) PH12013500761A1 (enExample)
RU (1) RU2013123062A (enExample)
SG (1) SG189935A1 (enExample)
WO (1) WO2012052463A1 (enExample)
ZA (1) ZA201303656B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
WO2019101700A1 (en) * 2017-11-21 2019-05-31 Nestec S.A. Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
WO2020163188A1 (en) * 2019-02-08 2020-08-13 Imbria Pharmaceuticals, Inc. Compositions containing n-acetylcysteine conjugated to a tca cycle intermediate
EP4049672A4 (en) * 2019-10-25 2023-11-29 Ajinomoto Co., Inc. Muscle quality improvement agent
WO2024068302A1 (en) 2022-09-30 2024-04-04 Evonik Operations Gmbh Probiotic composition for the treatment of malnutrition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
JPS62286923A (ja) * 1986-06-04 1987-12-12 Takao Shinoda 貧食作用増強剤
JPH05294833A (ja) * 1991-04-15 1993-11-09 Takeda Chem Ind Ltd ビタミン含有保健剤
WO1993002682A1 (en) * 1991-08-06 1993-02-18 Labco Pharmaceuticals, Inc. Method and compositions for reducing craving for alcohol and stimulants
DE4229166A1 (de) * 1992-09-01 1994-03-03 Deutsches Krebsforsch Mittel zur Aufrechterhaltung und/oder Steigerung der Muskelleistung und Körperzellmasse
FR2711529B1 (fr) 1993-10-28 1996-07-05 Clintec Nutrition Cy Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.
US5627152A (en) * 1995-01-18 1997-05-06 Telluride Pharmaceutical Corporation Method for increasing bodyweight
US5770217A (en) 1997-07-02 1998-06-23 Atlatl, Inc. Dietary supplement for hematological, immune and appetite enhancement
RO119122B1 (ro) * 1998-02-02 2004-04-30 Dumitru Dobrescu Medicament geriatric
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
MXPA03007802A (es) * 2001-03-09 2003-12-08 Nestle Sa Composicion que mejora las deficiencias fisiologicas relacionadas con la edad y que incrementa la longevidad.
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
CA2620313C (en) 2005-06-14 2011-08-02 Nestec S.A. Nutritional method for elderly people
DE102005062417A1 (de) * 2005-12-27 2007-08-23 Korth, Ruth-Maria, Dr.med. Kompositionen mit spezifischen und unspezifischen Lipidantagonisten
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
JP2008201711A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd システイン臭が低減された固形製剤
JP2009001507A (ja) * 2007-06-19 2009-01-08 Ss Pharmaceut Co Ltd 体脂肪減少剤およびその利用
WO2009157759A1 (en) * 2008-06-23 2009-12-30 N.V. Nutricia Nutritional composition for improving the mammalian immune system
TWI515005B (zh) 2008-09-12 2016-01-01 ２４５８７８１加拿大公司 在接受化療或放療的患者中應用富含半胱胺酸之乳清衍生蛋白以增進患者存活時間
ES2621936T3 (es) 2008-10-17 2017-07-05 Nestec S.A. Método para preparar composiciones de proteína de suero de leche

Also Published As

Publication number Publication date
US20130225486A1 (en) 2013-08-29
WO2012052463A1 (en) 2012-04-26
JP2014504261A (ja) 2014-02-20
EP2629769A1 (en) 2013-08-28
EP2629769B1 (en) 2017-10-04
AU2011317627B2 (en) 2016-06-02
SG189935A1 (en) 2013-06-28
CA2815109A1 (en) 2012-04-26
JP6160832B2 (ja) 2017-07-12
MX2013004371A (es) 2013-08-27
ZA201303656B (en) 2014-11-26
ES2654344T3 (es) 2018-02-13
EP2444083A1 (en) 2012-04-25
CA2815109C (en) 2020-03-24
DK2629769T3 (en) 2018-01-02
US9233090B2 (en) 2016-01-12
RU2013123062A (ru) 2014-11-27
PH12013500761A1 (en) 2017-08-23
CN103269697A (zh) 2013-08-28
AU2011317627A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
BR112013009709A2 (pt) cisteína e absorção de alimento
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
CL2014000801A1 (es) Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112016003723A2 (pt) sanitização de alimento
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
EP3038474A4 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
MX2015010139A (es) Composicion antiseptica oral para tratamiento de mucositis oral.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX342947B (es) Tratamiento de diabetes tipo 2.
EP3310366A4 (en) Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
BRPI0610786B8 (pt) uso de um ou mais oligossacarídeos ácidos e neutros, e cisteína e/ou fonte de cisteína, e, composição alimentícia
ES2711427T8 (es) Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
UA107687C2 (ru) Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен.
MX2019007555A (es) Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.
EA201491426A1 (ru) Новые фармацевтические композиции, содержащие фосфатидилсерин и куркумин
BR112015025760A2 (pt) produto de massa ou massa crua compreendendo grãos funcionalizados
BR112014000795A2 (pt) uso cosmético e/ou dermatológico de compostos oligossacarídeos na prevenção e no tratamento de estrias
TR201908639T4 (tr) Dejeneratif göz bozukluklarının önlenmesi ve veya tedavisine yönelik safran bazlı bileşimler.
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
DK2193789T3 (da) Anvendelse af 3,5-dihydroxytoluen eller derivater deraf i fremstillingen af medicin og funktionelle fødevarer til behandling eller forebyggelse af depression
PH12015502242A1 (en) Lutein composition suitable for infant food formulations
MX374340B (es) Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: SOCIETE DES PRODUITS NESTLE S.A. (CH)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]